Compare VEEV & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEV | INSM |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4B | 30.1B |
| IPO Year | 2013 | 2000 |
| Metric | VEEV | INSM |
|---|---|---|
| Price | $166.45 | $101.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 24 |
| Target Price | ★ $280.42 | $201.17 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.93 | N/A |
| EPS | ★ 5.44 | N/A |
| Revenue | ★ $1,104,081,000.00 | N/A |
| Revenue This Year | $14.42 | $182.31 |
| Revenue Next Year | $12.17 | $65.19 |
| P/E Ratio | $30.88 | ★ N/A |
| Revenue Growth | ★ 28.05 | N/A |
| 52 Week Low | $148.05 | $64.85 |
| 52 Week High | $310.50 | $212.75 |
| Indicator | VEEV | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 21.12 |
| Support Level | $150.18 | N/A |
| Resistance Level | $175.04 | $166.81 |
| Average True Range (ATR) | 5.45 | 6.60 |
| MACD | 1.44 | -3.45 |
| Stochastic Oscillator | 60.57 | 5.90 |
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.